# DZD8586

Source: https://onco.cc/drugs/dzd8586/  
OnCo record `dzd8586` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.

## Summary

DZD8586 is a small-molecule drug developed by Dizal Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07139873 (A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)), in chronic lymphocytic leukaemia and diffuse large B-cell lymphoma. The largest, NCT07139873, plans to enrol 250 participants with primary completion expected 2029-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Birelentinib
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of DZD8586: https://clinicaltrials.gov/search?intr=DZD8586
- Sponsor page: https://www.dizalpharma.com

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)
- trials: [A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)](https://onco.cc/trials/nct07154264/), [A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)](https://onco.cc/trials/tai-shan6/), [DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)](https://onco.cc/trials/nct07059650/), [DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)](https://onco.cc/trials/nct06539182/)

---
JSON: https://onco.cc/api/v1/entities/dzd8586.json